Product Pipeline - Development

KI-0001
MRI agent for tumor detection

Imaging angiogenesis via the avB3 integrin biomarker, KI-0001 can find tumors as small as 1-2 mm in size, while also highlighting actively growing regions in the tumor margin. By monitoring angiogenesis, KI-0001 also offers the opportunity to monitor response to anti-angiogenic therapies.


KI-0001 Tumor Detection Human melanoma in mouse
1.5T MRI

KI-100X
Targeted chemotherapeutics for solid tumors

In animal models, these Kereos products have been shown to aggressively reduce angiogenesis in both tumor and atherosclerosis models, as well as inhibit tumor growth. With KI-0001, candidates from this series of products form a powerful diagnostic/ therapeutic pair.


KI-0002
MRI agent for cardiovascular disease detection

Kereos is collaborating with Lantheus (formerly known as Bristol-Myers Squibb) for its second MRI agent for targeted assessment of cardiovascular disease via an undisclosed biomarker.

KI-1004
Anti-restenotic

Using the avB3 integrin biomarker to selectively deliver rapamycin to post-angioplasty vascular smooth muscle, KI-1004 has been shown to effectively inhibit restenosis while preserving re-endotheliazation in angioplasty models.

KM-4419
Targeted chemotherapeutic for solid tumors

Exploiting a particular vulnerability of many tumors, this clinical-stage candidate targets a key pathway in cancer cell survival. In animal models, KM-4419 synergizes with several standard-of-care chemotherapeutics in blocking tumor growth and increasing survival.